John Theurer Cancer Center
Hackensack Meridian Health
Hackensack Meridian Health
The treatment of multiple myeloma is highly personalized at John Theurer Cancer Center, part of Hackensack University Medical Center in New Jersey. We are one of the few treatment centers in the nation offering a full team of specialized experts in the care of patients with all stages of multiple myeloma. If you have multiple myeloma, we carefully assess the stage and biology of your disease to match you with the best treatment, or to customize a surveillance program for you if you do not yet need therapy. When you come to us for your care, you’ll see the same physician at every visit who gets to know you and your family, is available to address your questions and concerns, and provides a personal level of care that can be hard to find elsewhere.
We bring together all the multiple myeloma experts you may need—offering dedicated highly specialized providers trained at the world’s best academic medical centers—from hematology/medical oncology, immunology, stem cell transplantation, infectious diseases, pathology, radiation oncology, orthopedics, and nursing to provide you with a tailored plan of care based on the specific features of your disease and your personal condition. Our goal is to treat your myeloma while taking into account all physical, functional, emotional, and quality of life aspects of your disease. We don’t just care for you, but about you.
Some people have diseases that have the potential to turn into multiple myeloma. These “precursor” disorders include smoldering multiple myeloma and MGUS (monoclonal gammopathy of undetermined significance). If you were diagnosed with one of these disorders, you may have been surprised because they don’t cause any symptoms. Our doctors take a conservative approach to treating patients with smoldering multiple myeloma and MGUS. We’ll monitor you and let you know if or when you may benefit from treatment. We also offer clinical trials assessing immunological factors and other predictors of the best time to start treatment.
We are doing this study to learn if the MMprofiler genomic test can help your doctor in making decisions about your treatment.
The purpose of this study is to evaluate the safety of the study drug, GSK2857916, at different doses and how well it works to treat people with multiple myeloma when taken together with Lenalidomide Plus Dexamethasone (Treatment Arm A), or Bortezomib Plus Dexamethasone (Treatment Arm B).
Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).
This research study is being done to learn more about multiple myeloma and if the study drug, GSK2857916, can improve multiple myeloma in patients who have already failed other treatments.
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms.
The purpose of the Molecular Profiling Initiative (MPI) is to provide timely CLIA genomic sequencing information to MM patients and their doctors, allowing them to make informed treatment decisions and identify potential treatment options based on a patient’s genomic alterations.
This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as monotherapy and in combination with dexamethasone.
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia.
This phase I/II trial studies the side effects and best dose of idasanutlin and ixazomib citrate when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement.
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma.
This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies.
The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.
Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (bb21217). Following manufacture of the drug product, subjects will receive lymphodepletion prior to bb21217 infusion.
High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant recipients worldwide for the same or similar disorders.
This study will find the highest acceptable treatment dose and timing of infusion of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with multiple myeloma.
In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.
This is an open-label, multicenter, Phase 1/2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed or refractory multiple myeloma.
30 Prospect Avenue
Hackensack, NJ 07601
Create your account today and get matched to myeloma treatment centers and specialists around the US.
Weekdays 9am - 5pm EST